Groundbreaking Gene Therapy Study Gets The Go-Ahead By The FDANelson Vergel
Calimmune, a small biotechnology company, is giving people a low dose chemo agent (as conditioning) and then infusing them with stem cells that have been modified to inhibit the CCR5 receptor and to contain their own built-in HIV fusion inhibitor peptide, thereby blocking two sites that are essential for HIV infection.
The study is enrolling only for HIV+ people who have an R5 virus and who are not taking HIV medications due to their own choice (side effects, etc) for at least 6 weeks. Over 500 CD4 cells required. Very promising approach by Calimmune!
This is the Los Angeles investigator. San Francisco also has a site but it has been fully enrolled